Vyriad

Developer of oncolytic-virus-based immunotherapies for cancer treatment. The company focuses on the development of new oncolytic virus treatments that leverage Vyriad’s vesicular stomatitis virus (VSV) platform, as well as antibody discovery capabilities. The company's lead product is Voyager-V1 which addresses multiple cancer types.